With the approval of new therapies that are restricted based on PD-L1 expression, there are many different assays to test for this. In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, discusses whether these tests are equivalent in terms the patients that are selected to receive the therapy and whether their clinical outcomes are the same. This interview was conducted at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
Problems with PD-L1 expression testing in patients with NSCLC
